Virios Therapeutics, Inc.

Virios Therapeutics, Inc. is a biotechnology company specializing in the development of antiviral therapies to address diseases linked to abnormal immune responses triggered by viruses. The company's primary focus is on the development of IMC-1, a fixed dose combination of famciclovir and celecoxib for fibromyalgia treatment, and IMC-2, a combination of valacyclovir and celecoxib to manage symptoms associated with long COVID. By leveraging these innovative therapies, Virios Therapeutics, Inc. aims to generate revenue through the commercialization of its antiviral treatments, catering to the unmet medical needs of patients suffering from these conditions.